iptacopan   Click here for help

GtoPdb Ligand ID: 10710

Synonyms: compound 41 [PMID: 32073845] | Fabhalta® | LNP-023 | LNP023
Approved drug PDB Ligand Immunopharmacology Ligand
iptacopan is an approved drug (FDA (2023))
Compound class: Synthetic organic
Comment: Iptacopan (LNP023) is a small molecuile, orally bioavailable complement factor B inhibitor [1,3]. Factor B is a serine protease, that is a component of the alternative pathway (AP) of the complement system. The AP acts as an amplification loop of complement activation and contributes to various human diseases. Inhibition of factor B is being expolited as a mechanism to treat complement-mediated conditions such as C3 glomerulopathy (glomerulonephritis, including IgA nephropathy), paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 74.79
Molecular weight 422.22
XLogP 4.27
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCO[C@H]1CCN([C@@H](C1)c1ccc(cc1)C(=O)O)Cc1c(OC)cc(c2c1cc[nH]2)C
Isomeric SMILES CCO[C@H]1CCN([C@@H](C1)c1ccc(cc1)C(=O)O)Cc1c(OC)cc(c2c1cc[nH]2)C
InChI InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1
InChI Key RENRQMCACQEWFC-UGKGYDQZSA-N
Immunopharmacology Comments
LNP023 is a complement factor B inhibitor that was designed for potential to treat complement mediated diseases [1]. It has progressed to clinical evaluation in a set of diverse diseases that share pathological activation of the alternative complement pathway.